je.st
news
Tag: rtk
NFMS 2016: Fertilizer application, planters, RTK, heads, cover crops and more
2016-04-02 03:49:00| Corn & Soybean Digest
The 2016 National Farm Machinery Show offered so much for farmers. From new fertilizer application to cover crop seeders, new planters and tractors to grain conditioning, and more, these are some of the products we thought you should definitely see. read more
Tags: more
application
cover
heads
Swift Navigation raises $11M Series-A round for high-accuracy RTK GPS for autonomous vehicles
2015-12-09 12:55:30| Green Car Congress
Tags: navigation
round
gps
vehicles
GNSS RTK Receiver targets unmanned aerial systems.
2015-10-01 14:31:08| Industrial Newsroom - All News for Today
Featuring 25 x 25 mm form factor, 300 mW Model S2525F8-BD-RTK simultaneously tracks up to 28 satellites and supports GPS, BDS, QZSS, and SBAS. Receiver operates in both base station and rover modes. As rover, device receives RTCM 3.0 or 3.1 data from base station, or raw measurements from another S2525F8-BD-RTK receiver serving as base station, and performs carrier phase RTK processing to achieve relative positioning with 1 cm + 1 ppm position accuracy within 10 Km baseline.
Tags: systems
targets
receiver
aerial
M2M Connectivity Launches The L1 RTK + Heading GNSS Receiver From NVS Technologies
2015-09-15 09:18:28| wirelessdesignonline News Articles
M2M Connectivity launches the latest L1 RTK+Heading GNSS receiver from NVS Technologies in the Australia and New Zealand market. The NV08C-RTK-A is a fully integrated multi-constellation satellite navigation receiver with embedded RTK functionality.
Tags: technologies
heading
receiver
connectivity
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
2015-03-05 00:30:00| Merck.com - Product News
Dateline City: TOKYO & KENILWORTH, N.J. Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. Language: English Contact: Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more